These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25974285)

  • 1. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology.
    Costabile G; d'Angelo I; Rampioni G; Bondì R; Pompili B; Ascenzioni F; Mitidieri E; d'Emmanuele di Villa Bianca R; Sorrentino R; Miro A; Quaglia F; Imperi F; Leoni L; Ungaro F
    Mol Pharm; 2015 Aug; 12(8):2604-17. PubMed ID: 25974285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
    Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
    J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a dry, stable and inhalable acyl-homoserine-lactone-acylase powder formulation for the treatment of pulmonary Pseudomonas aeruginosa infections.
    Wahjudi M; Murugappan S; van Merkerk R; Eissens AC; Visser MR; Hinrichs WL; Quax WJ
    Eur J Pharm Sci; 2013 Mar; 48(4-5):637-43. PubMed ID: 23277289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
    Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
    J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing.
    Imperi F; Massai F; Ramachandran Pillai C; Longo F; Zennaro E; Rampioni G; Visca P; Leoni L
    Antimicrob Agents Chemother; 2013 Feb; 57(2):996-1005. PubMed ID: 23254430
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Collalto D; Giallonardi G; Fortuna A; Meneghini C; Fiscarelli E; Visca P; Imperi F; Rampioni G; Leoni L
    Front Microbiol; 2022; 13():845231. PubMed ID: 35547141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
    Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
    Chang RYK; Chen K; Wang J; Wallin M; Britton W; Morales S; Kutter E; Li J; Chan HK
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection.
    Song Z; Wu H; Mygind P; Raventos D; Sonksen C; Kristensen HH; Høiby N
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3868-74. PubMed ID: 16127064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide.
    d'Angelo I; Casciaro B; Miro A; Quaglia F; Mangoni ML; Ungaro F
    Colloids Surf B Biointerfaces; 2015 Nov; 135():717-725. PubMed ID: 26340361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.
    Yu S; Pu X; Ahmed MU; Yu HH; Mutukuri TT; Li J; Zhou QT
    Int J Pharm; 2021 Dec; 610():121160. PubMed ID: 34624446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.
    Porsio B; Cusimano MG; Schillaci D; Craparo EF; Giammona G; Cavallaro G
    Biomacromolecules; 2017 Dec; 18(12):3924-3935. PubMed ID: 29111673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.
    Hoffmann N; Lee B; Hentzer M; Rasmussen TB; Song Z; Johansen HK; Givskov M; Høiby N
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3677-87. PubMed ID: 17620382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint Intratracheal Surfactant-Antibacterial Therapy in Experimental Pseudomonas-Induced Pneumonia.
    Birkun AA; Kubyshkin AV; Novikov NY; Krivorutchenko YL; Fedosov MI; Postnikova ON; Snitser AA
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):299-307. PubMed ID: 25517041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice.
    Wu H; Song Z; Hentzer M; Andersen JB; Molin S; Givskov M; Høiby N
    J Antimicrob Chemother; 2004 Jun; 53(6):1054-61. PubMed ID: 15117922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
    Alhajj N; Yahya MFZR; O'Reilly NJ; Cathcart H
    Eur J Pharm Sci; 2024 Jan; 192():106654. PubMed ID: 38013123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.